Jason J Luke
University of Pittsburgh · UPMC Hillman Cancer Center · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
7
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
NIH RePORTER
Trial papers
63
PubMed author-name match
Trials
Studies that name Jason J Luke as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:56 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06069570 · Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone MetastasesKiromic BioPharma Inc. · recruiting · Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors · principal investigator
- Ph1/Ph2NCT04655157 · Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaJason J. Luke, MD · terminated · Melanoma · principal investigator
- Ph2NCT04439357 · Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- Ph2NCT04439318 · Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- Ph2NCT04056910 · Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsJason J. Luke, MD · completed · Advanced Solid Tumor, IDH1 Mutation, Glioma · principal investigator
- Ph2NCT03304639 · Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell CarcinomaNational Cancer Institute (NCI) · completed · Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 · principal investigator
- Ph2NCT01835145 · Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2024 to 2025 · $485,600 awarded in 2025Same name and institution; not confirmed by an ID
- Immune Exclusion in Cancer ImmunotherapyR01DE031729 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2022 to 2024 · $592,843 awarded in 2024Same name and institution; not confirmed by an ID
- NCI ETCTN Pittsburgh Cancer Consortium (PCC)UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2020 to 2024 · $442,721 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT04439357, NCT04439318
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT04439357, NCT04439318
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT03304639, NCT01835145
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT01835145
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:56 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- 774 citationsRCR 93.8
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.J Clin Oncol · 2018506 citationsRCR 15.9
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.J Clin Oncol · 2013463 citationsRCR 12.8
- 456 citationsRCR 30.1
- Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.Clin Cancer Res · 2022366 citationsRCR 22.5
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.Cancer Discov · 2020298 citationsRCR 11.1
- Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.Clin Cancer Res · 2023242 citationsRCR 18.0
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.J Clin Oncol · 2021184 citationsRCR 8.3
- Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.Cancer Discov · 2021173 citationsRCR 8.1
- Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.Clin Cancer Res · 2023161 citationsRCR 13.0